Exosome Diagnostics and Therapeutics: Global Markets 2021-2026

Table of Contents

Chapter 1 Introduction

• Study Goals and Objectives
• Reasons for Doing This Study
• Scope of Report
• Information Sources
• Methodology
• Intended Audience
• What's New in This Report?
• Geographic Breakdown
• Analyst's Credentials
• Custom Research
• Related Reports

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

• Exosome Definition and Nomenclature
• Discovery of Exosomes
• Exosomes Biogenesis and Processing
• Exosome Components
• DNA in Exosomes
• Proteins in Exosomes
• RNA in Exosomes
• Isolation and Detection of Exosomes
• Isolation Techniques
• Exosome Detection
• Bioinformatics Databases for Exosome Research and Product Development
• ExoCarta
• Vesiclepedia
• EVpedia
• Exosome Function and Physiology

Chapter 4 Impact of COVID-19 on the Exosome Therapeutics Market

• Overview
• Current Outlook
• Exosome and COVID-19 Treatment

Chapter 5 Exosome Diagnostics Market

• Exosomal Proteins as Diagnostic Biomarkers
• Exosomal Nucleic Acids as Diagnostic Biomarkers
• Cancer Diagnostics as Market Potential for Exosome-Based Diagnostic Product Development
• Prostate Cancer Diagnostics Development in the Exosome Sector
• Breast Cancer as Potential for Diagnostic Development in the Exome Sector
• Bladder Cancer as Potential for Diagnostic Development in the Exosome Sector
• Ovarian Cancer as Potential for Diagnostic Development in the Exome Sector
• Lung Cancer as Potential for Diagnostic Development in the Exosome Sector
• Liquid Biopsy as Potential for Diagnostics in the Exome Sector
• Exosomal Proteins and Nucleic Acids as Cancer Biomarkers in Assay Development
• CNS Disorders and Neurodegeneration Diseases as Market Potential for Exosome Diagnostics Product Development
• Infectious Diseases as Market Potential for Exosome Diagnostic Product Development
• Cardiovascular Diseases as Market Potential for Exosome Diagnostic Product Development
• Prenatal Testing as Market Potential for Exosome Diagnostic Product Development
• Organ Transplantation as Market Potential for Exosome Diagnostic Product Development
• Market Participants in the Exosome-Based Diagnostics Sector
• Companies
• Evaluation of the Current Diagnostics Sector in the Exosome Market

Chapter 6 Exosome Therapeutics Market

• Intrinsic Therapeutic Activity of Exosomes
• Immunological Compatibility
• Cargo Capabilities
• Generation of Exosome-Mediated Therapeutics
• Exosome Isolation and Purification from Biofluids or Cell Culture
• Engineering Exosomes as Therapeutic Delivery Vehicles
• Targeting Exosomes to Specific Recipient Cells
• Designing Exosomes as a Synthetic Vector
• Market Potential for Exosome Therapeutics
• Market Participants in the Exosome-Based Therapeutics Sector
• Companies
• Evaluation of the Current Therapeutics Sector in the Exosome Market

Chapter 7 Exosome Reagents and Research Tools Market

• Market Overview
• Isolation Methodologies and Reagents for Exosome
• Detection Methodologies and Reagents for Exosome Research
• Characterization Methods and Reagents for Exosome Research
• Engineering Methods and Reagents for Exosome Research
• Additional Products and Reagents for Exosome Research
• Market Participants in Reagents and Tools for Exosome Research
• Companies
• Evaluation of Current Tools and Reagents in the Exosome Market

Chapter 8 Global Exosome Therapeutics and Diagnostics Market by End User

• Cancer Institutes
• Hospital and Diagnostic Centers
• Exosomal Proteins as Diagnostic Biomarkers
• Exosome Nucleic Acids as Diagnostics Biomarkers
• Exosomes: Novel Biomarkers for Clinical Diagnosis
• Others: Pharmaceutical and Life Science Industries and Academic Institutes

Chapter 9 Global Exosome Therapeutics and Diagnostics Market by Region

• North America
• Europe
• Asia-Pacific
• Rest of the World

Chapter 10 Impact of Exosome Research on Specific Biopharmaceutical Markets

• Biomarker and Diagnostic Industry
• MicroRNA Market
• Liquid Biopsy Market
• Stem Cell Technologies Market
• Prenatal Diagnostic Market
• Agriculture and Food Industry
• Microfluidics and Nanotechnology
• Skincare Industry

Chapter 11 Patents and Pipeline Analysis

• U.S. Patent Analysis
• European Patent Analysis
• Japanese Patent Analysis
• Pipeline Analysis

Chapter 12 Market Summary

Chapter 13 Company Profiles

• Codiak Biosciences
• Evox Therapeutics Ltd.
• Exosome Diagnostics Inc.
• Hansabiomed Life Sciences Ltd. (Lonza)
• Nanosomix Inc.
• System Biosciences (SBI)

List of Tables
Summary Table: Global Market for Exosome Diagnostics and Therapeutics, by Application, Through 2026
Table 1: Nomenclature of Exosome Particles
Table 2: Publication Trend about Exosome, 2010-2020
Table 3: Molecules Involved in Exosome Biogenesis and/or Release
Table 4: Steps in Exosome Biogenesis and Processing
Table 5: Proteins Essential in Exosome Biogenesis and Processing
Table 6: Proteins Found in Exosomes
Table 7: MicroRNA in Different Bodily Fluids, by Sample
Table 8: Methods for Exosome Isolation
Table 9: Distribution of Exosomes Isolation Procedures in the Studies Cataloged in ExoCarta
Table 10: Data Cataloged in ExoCarta, 2012 and 2017
Table 11: Data Cataloged in Vesiclepedia, 2012, 2017 and 2020
Table 12: Data Cataloged in EVpedia, 2018
Table 13: Comparison of Databases for Exosome Studies
Table 14: Coronavirus Reported Cases and Deaths, by Country, as of May 2021
Table 15: Examples of Exosomal Proteins for Clinical Diagnostic Applications
Table 16: Examples of Exosomal MicroRNA for Clinical Diagnostic Applications
Table 17: Characteristic Exosomal MicroRNAs in Various Biological Fluids
Table 18: Expression Status of MicroRNAs as the Exosomal Cargo in Different Cancer Types
Table 19: Exosomal Protein Biomarkers for Diagnosis of Different Cancers
Table 20: Exosomal Nucleic Acid Biomarkers for Diagnosis of Different Cancers
Table 21: Statistics for Prostate Cancer, 2021
Table 22: Studies of microRNAs in PCa Patients
Table 23: Global Market for Prostate Cancer Diagnostics and Related Cost, 2017 and 2022
Table 24: Statistics for Breast Cancer, 2021
Table 25: Global Market for Breast Cancer Diagnostics, Through 2024
Table 26: U.S. Statistics for Bladder Cancer, 2021
Table 27: Functions of Exosomal Noncoding RNAs and Proteins in Tumor Metastasis and Invasion
Table 28: Global Market for Bladder Cancer Diagnostics, 2017
Table 29: Statistics for Ovarian Cancer, 2021
Table 30: MicroRNA Content of Ovarian Cancer-Derived Exosomes
Table 31: Global Market for Ovarian Cancer Diagnostics, Through 2022
Table 32: Summary of the Predictive Exosomal Components Described Until Now, Including Utility and Values Represented, by Sensitivity
Table 33: Statistics for Lung Cancer, 2021
Table 34: Global Market for Lung Cancer Diagnostics, 2019
Table 35: Differences between Liquid and Tissue Biopsy for Cancer Detection and Evaluation
Table 36: Global Market for Liquid Biopsy including Research Tools, Services and Diagnostics, Through 2025
Table 37: Exosomal Protein Biomarkers from Bodily Fluids of Patients in Pre-Clinical and Clinical Studies
Table 38: Exosomal Nucleic Acid Biomarkers in Pre-Clinical and Clinical Studies
Table 39: U.S. Statistics for Alzheimer’s Disease, 2021
Table 40: Global Market for Alzheimer’s Disease Therapeutics and Diagnostics, Through 2025
Table 41: Global Statistics for Hepatitis C Infection, 2020
Table 42: Estimated Actual New Cases of HAV (Range), 2016 and 2019
Table 43: Global Market for Hepatitis C Diagnostics, 2017
Table 44: U.S. Statistics for Cardiovascular Diseases, 2020
Table 45: Global Market for Cardiovascular Diagnostics, 2020
Table 46: Global Market for Prenatal Diagnostics, Predictive Tests and Neonatal Monitoring, Through 2023
Table 47: Global Market for Organ and Tissue Transplantation Products and Devices, Through 2024
Table 48: Comparison of Exosome Diagnostics’ Approach to Other Liquid Biopsy Platforms
Table 49: Main Market Participants in Exosome-Based Diagnostics Sector
Table 50: Global Market for Exosome Diagnostics, Through 2026
Table 51: Examples of Studies Using Extracellular Vesicles as Drug Delivery Vehicles
Table 52: Examples of Engineering Exosome for Cargo Delivery
Table 53: Type of Cargo and Loading Method
Table 54: Examples of Physiological Effect of Exosome Delivery
Table 55: Global Rankings of Top 10 Vaccine Manufacturers, 2020
Table 56: Global Elderly Population with Alzheimer’s Dementia, by Age Group, 2021
Table 57: Global Prevalence of Tuberculosis, 2015-2019
Table 58: Global Prevalence of Cancer, 2010-2017
Table 59: U.S. Statistics for Burn Injuries
Table 60: U.S. Statistics for Pressure Ulcers
Table 61: Global Market for Aethlon Medical, 2016-2021
Table 62: Global Market Revenue, Cost and Profits for Capricor Therapeutics, 2016-2020
Table 63: Main Market Participants in Exosome-based Therapeutics Sector
Table 64: Examples of Financing for Exosome-based Therapeutics, by Company, Through 2017
Table 65: Global Market for Exosome Therapeutics, Through 2026
Table 66: Main Steps in Exosome Research Approach
Table 67: Examples of Commercial Kits and Reagents for Exosome Isolation
Table 68: Frequency of Use for Each Isolation Technique for Exosome Purification
Table 69: Range of Model Options with Zetasizer Nano ZS Instrument
Table 70: Examples of Detection Assay
Table 71: Examples of Antibody Providers for Exosome Research
Table 72: Commercial RNA Extraction Kits
Table 73: Use of Characterization Techniques for Exosome Samples
Table 74: Examples of Purified Exosomes Commercial Products
Table 75: Main Market Participants in Exosome Research Tools and Reagents
Table 76: Global Market for Exosome Research Tools and Reagents, Through 2026
Table 77: Global Market for Exosome Therapeutics and Diagnostics, by End User, Through 2026
Table 78: Global Market for Exosomes in Cancer Institutes, by Region, Through 2026
Table 79: Studies Employing Exosomes without Genetic Modification in Cancer Treatment
Table 80: In Vivo and In Vitro Studies Using Modified Exosomes for Cancer Therapy
Table 81: List of Exosomal Bioactive Molecules Involved in Various Progressions
Table 82: Global Market for Exosomes in Hospitals and Diagnostics Centers, by Region, Through 2026
Table 83: Exosome Proteins in Clinical Diagnostics Applications
Table 84: Exosomes: Novel Biomarkers for Clinical Diagnosis
Table 85: Global Market for Exosomes in the Others End User Segment, by Region, Through 2026
Table 86: Global Market for Exosome Diagnostics and Therapeutics, by Region, Through 2026
Table 87: Leading Cause of Deaths Related to Cancer in the UAE, by Cancer Type, 2018
Table 88: Leading Causes of Death in Argentina, and Percent Change, 2005-2016
Table 89: Examples of Protein Markers in Exosomes and Their Related Pathologies
Table 90: Examples of MicroRNA Markers in Exosomes and Their Related Pathologies
Table 91: Comparison Between Liquid Biopsy and Tissue Biopsy
Table 92: Major Companies Researching and Producing Exosome Products
Table 93: U.S. Patents on Exosome Diagnostics and Therapeutics, January 2015-September 2021
Table 94: European Patents on Exosome Diagnostics and Therapeutics, January 2015-September 2021
Table 95: Japanese Patents on Exosome Diagnostics and Therapeutics, Jan. 2016-Sept. 2021
Table 96: Clinical Trials on Various Exosome Molecules
Table 97: Global Market for Exosome Diagnostics and Therapeutics, by Application, Through 2026
Table 98: Main Participants in the Exosome Market
Table 99: Product Portfolio: Codiak Biosciences
Table 100: Recent Development: Codiak Biosciences
Table 101: Product Portfolio: Evox Therapeutics Ltd.
Table 102: Recent Development: Evox Therapeutics Ltd.
Table 103: Product Portfolio: Exosome Diagnostics Inc.
Table 104: Recent Developments: Exosome Diagnostics Inc.
Table 105: Product Portfolio: HansaBioMed Life Sciences Ltd. (Lonza)
Table 106: Recent Developments: HansaBioMed Life Sciences Ltd. (Lonza)
Table 107: Product Portfolio: Nanosomix Inc.
Table 108: Product Portfolio: System Biosciences (SBI)

List of Figures
Summary Figure: Global Market for Exosome Diagnostics and Therapeutics, by Application, 2019-2026
Figure 1: Publication Trends for Exosomes, 2010-2020
Figure 2: Differential Centrifugation Process
Figure 3: Ciliated Porous Device Designed to Isolate Exosomes, by Filtration
Figure 4: Sieving Models for Exosome Filtration
Figure 5: Workflow of MiRNA-Based Therapeutic Delivery Using Exosomes to Treat Alcoholic Liver Disease
Figure 6: Global Market for Exosome Diagnostics, 2019-2026
Figure 7: Global Prevalence of Cancer, 2010-2017
Figure 8: Global Market for Exosome Therapeutics, 2019-2026
Figure 9: Global Market for Exosome Research Tools and Reagents, 2019-2026
Figure 10: Global Cancer Prevalence, 2005-2016
Figure 11: Global Incidence of Patients with Chronic Diseases, 2005-2030
Figure 12: U.S. Patent Documents by Published, Filed and Granted Dates, 2015-2021
Figure 13: European Patent Documents by Published, Filed and Granted Dates, 2015-2021
Figure 14: Japanese Patent Documents by Published, Filed and Granted Dates, 2015-2021
Figure 15: Shares of Clinical Trials on Exosomes, by Phase, 2021
Figure 16: Global Market for Exosome Diagnostics and Therapeutics, by Application, 2019-2026

Samples

Executive Summary

Initially, exosome particles were considered “garbage” molecules secreted by cells. Today, many researchers are convinced that these tiny vesicles have unlimited potential in diagnostics and therapeutics, especially in oncology treatments.

By definition, exosomes are small membrane sacs/vesicles, approximately 30 to 100 nanometers (nm) in diameter, that are released by both healthy and cancerous cells. Substances from cell cytoplasm - such as genomic DNA, various RNA species, proteins, and lipids - are encapsulated into exosomes and shed into the extracellular environment.

Research shows that all fluids in the human body contain exosomes, which can transfer cytoplasmic ingredients to other cells either locally or at distant sites. Once they reach the recipient cells, cytoplasmic ingredients can alter their biology. Thus, exosomes are being widely adopted by several end-users, including hospitals, diagnostics centers and research institutions.

Scientists believe that various biomolecules in exosomes can be profiled and, consequently, may serve as useful biomarkers for different diseases. Nucleic acids such as RNA or DNA can be isolated from exosomes and further analyzed by various techniques. This is now efficiently done with the use of the software provided by key players. The software used in exosome therapeutic and diagnostic applications is used for extraction, isolation and other purposes.

This report evaluates the diagnostic market affected by exosome research and the further potential of exosome-based tests and assays. Indeed, an exosome approach represents the opportunity to expand and develop the liquid biopsy market, a growing sector in cancer diagnostics. Thus, increasing cancer prevalence worldwide generates huge opportunities for the liquid biopsy market. According to Our World in Data, about 42 million people worldwide had cancer in 2016, a more than two-fold increase from 1990.

This report also highlights developments in the therapeutic and drug development sectors. There is a significant potential for using exosome depletion as a way of treating disease; cancer-generated exosomes can inhibit the immune response and stimulate angiogenesis, the development of new blood vessels. Consequently, if these exosomes are removed, tumor growth might be inhibited, and anticancer agents can work more efficiently.

In addition, there is a potential for exosomes to be used as targeted delivery vehicles of therapeutic molecules to cancer cells - for example, delivering small interfering RNA-specific molecules (siRNA) for a particular oncogene expressed in a tumor cell. According to the U.S. National Library of Medicine, cell-based exosomes have a large number of roles and targets. Also, various studies have shown that exosomes have the potential to deliver various types of cargo to target cells efficiently.

Companies Mentioned

• Codiak Biosciences
• Evox Therapeutics Ltd.
• Exosome Diagnostics Inc.
• Hansabiomed Life Sciences Ltd. (Lonza)
• Nanosomix Inc.
• System Biosciences (SBI)